ANI Pharmaceuticals Plans To Appeal Judge Sheldon K. Rennie's Decision To Deny ANI's Post-Trial Motions For New Trial, Judgement; Co. Seeks To Recover Assets' Value Sold to CG Oncology Under 2010 Deal

8-K filing — ANI PHARMACEUTICALS INC (ANIP)

Filed: 2026-08-24 AccNo: 0001023024-26-000071 Size: 173 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported strong Q2 earnings, affirmed FY2026 guidance, and saw changes in price targets by analysts.

Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119

Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and lowers the price target from $124 to $119.

Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90

Canaccord Genuity analyst Gary Nachman maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold and lowers the price target from $91 to $90.

RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79

Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $85

Piper Sandler analyst Kelsey Goodwin maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $82 to $85.